Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | JAK3 | P52333 | 4/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801990 | 0.89 | NPBWR1 (0.39) | NPBWR1JAK2JAK3JAK1BUB1 | |
| SCHEMBL1663154 | 0.89 | MAP3K14 (0.40) | NPBWR1JAK2JAK3JAK1BUB1 | |
| SCHEMBL12959677 | 0.88 | NPBWR1 (0.38) | NPBWR1JAK2JAK3JAK1BUB1 | |
| SCHEMBL12797055 | 0.87 | JAK3 (0.41) | JAK2JAK3JAK1PTK2LRRK2 | |
| SCHEMBL12796184 | 0.87 | JAK3 (0.39) | JAK2JAK3JAK1PTK2LRRK2 | |
| SCHEMBL1664795 | 0.85 | JAK3 (0.44) | JAK2JAK3USP1LRRK2 | |
| SCHEMBL12797305 | 0.84 | MAPT (0.38) | JAK2JAK3JAK1LRRK2 | |
| SCHEMBL1665604 | 0.83 | LRRK2 (0.48) | NPBWR1JAK2JAK3JAK1BUB1 | |
| SCHEMBL12801916 | 0.83 | JAK2 (0.49) | JAK2JAK3JAK1 | |
| SCHEMBL12801967 | 0.82 | LRRK2 (0.41) | NPBWR1JAK2JAK3JAK1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | claimed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | claimed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | NPBWR1 2415/4885JAK2 3/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.